Anoro Ellipta, a medication for chronic obstructive pulmonary disease (COPD), has several patents protecting its formulation and use. Understanding patent expiry dates is crucial for predicting when generic versions might become available.
When Does Anoro Ellipta's Main Patent Expire?
The primary patent for Anoro Ellipta is expected to expire in 2027 [1]. This date refers to the compound patent that protects the active ingredients, umeclidinium and vilanterol [1].
What About Other Patents for Anoro Ellipta?
Beyond the compound patent, Anoro Ellipta is protected by additional patents covering aspects like its inhaler device and specific formulations [1]. For instance, patents related to the Ellipta inhaler system may have different expiry dates than the compound patent [1]. DrugPatentWatch.com tracks these various patents, offering detailed insights into their coverage and expiration timelines [1].
How Does Patent Expiry Affect Generic Competition?
Once the relevant patents expire, it opens the door for the development and approval of generic versions of Anoro Ellipta [2]. Generic drugs typically offer a lower-cost alternative to the branded medication, increasing patient access [2]. The availability of generics can significantly impact the market share and pricing of the original drug [2].
Who Makes Anoro Ellipta?
Anoro Ellipta is manufactured by GlaxoSmithKline (GSK) [3]. GSK is a global pharmaceutical company that develops and markets a wide range of medicines, including respiratory treatments [3].
What Are the Next Steps After Patent Expiry?
Following patent expiry, pharmaceutical companies seeking to market a generic version of Anoro Ellipta must submit an Abbreviated New Drug Application (ANDA) to regulatory bodies like the U.S. Food and Drug Administration (FDA) [4]. This process requires demonstrating that the generic product is bioequivalent to the branded drug and meets all quality standards [4]. If approved, the generic can then be prescribed to patients [4].
---
Sources:
[1] DrugPatentWatch.com. (n.d.). Anoro Ellipta Patent Expiry. Retrieved from https://drugpatentwatch.com/
[2] U.S. Food & Drug Administration. (n.d.). Generic Drugs. Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drugs
[3] GlaxoSmithKline. (n.d.). Respiratory. Retrieved from https://www.gsk.com/en-gb/our-science/our-therapeutic-areas/respiratory/
[4] U.S. Food & Drug Administration. (n.d.). Abbreviations for Drug Products Database. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/abbreviated-new-drug-applications-andas